Aspirin Use After Biliary Tract Cancer Diagnosis

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, OCTOBER 17, 2019

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2019.4328?guestAccessKey=4b431465-c9dc-4248-b994-80f4c972fac7&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101719

 

What The Study Did: Researchers in this observational study examined if aspirin use after a diagnosis of a biliary tract cancer, which includes gallbladder cancer, was associated with reduced risk of death among nearly 3,000 patients.

Authors: Sarah S. Jackson, Ph.D., of the National Cancer Institute in Rockville, Maryland, is the corresponding author.

 

(doi:10.1001/jamaoncol.2019.4328)

Editor’s Note: The article includes funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.